Iambic Therapeutics Files for $100 Million Nasdaq IPO
NVIDIA-backed biotech Iambic aims to fund AI-designed cancer drugs and its lead candidate IAM1363 via public listing.
A high-resolution laboratory monitor displaying a colorful, rotating 3D molecular model of a small-molecule drug candidate.
Photo: Kronos News
Iambic Therapeutics has officially filed for a $100 million initial public offering on the Nasdaq [1]. The clinical-stage biotechnology company uses proprietary AI models to design small-molecule cancer therapies [2]. This move comes amid a wider surge in biotech filings throughout 2026 [3].
The company will use the funds to advance its drug pipeline, including lead candidate IAM1363 [1]. IAM1363 is a selective HER2 inhibitor currently undergoing clinical trials [2]. Iambic’s technology suite includes NeuralPLexer, an AI model developed with strategic backing from NVIDIA [1].
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
- 1.↗
bioxconomy.com
https://www.bioxconomy.com/investment/ai-drug-hunter-iambic-files-for-nasdaq-ipo
- 2.↗
investing.com
https://www.investing.com/news/stock-market-news/iambic-therapeutics-files-for-ipo-to-fund-cancer-drugs-93CH-4909715
- 3.↗
biospace.com
https://www.biospace.com/business/2026-ipo-blitz-continues-with-4-new-biotech-filings
Related stories
View all
About the author
Kronos News Desk covers news and editorial analysis for Kronos News.